EBO Stock Chart & Stats
AU$18.48
-AU$0.16(-0.88%)
At close: 4:00 PM EDT
AU$18.48
-AU$0.16(-0.88%)
Day’s Range― - ―
52-Week RangeAU$14.87 - AU$26.00
Previous CloseN/A
Volume47.74K
Average Volume (3M)97.19K
Market Cap
AU$3.50B
Enterprise ValueAU$6.29B
Total Cash (Recent Filing)AU$239.29M
Total Debt (Recent Filing)AU$1.90B
Price to Earnings (P/E)15.5
Beta0.46
Next Earnings
Feb 23, 2027EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend Yield6.34%
Share Statistics
EPS (TTM)1.07
Shares Outstanding209,062,880
10 Day Avg. Volume101,891
30 Day Avg. Volume97,189
Financial Highlights & Ratios
PEG Ratio-4.37
Price to Book (P/B)1.55
Price to Sales (P/S)0.33
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$23.31Price Target Upside26.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.96
Revenue Forecast (FY)AU$11.33B
Bulls Say, Bears Say
Bulls Say
Distribution Productivity And Lower Capital NeedsThe completed distribution-centre renewal strengthens EBOS’s operating platform and should improve throughput over time. Higher productivity, combined with normalised capital expenditure, can support stronger free cash flow and leave more capital available for organic growth or disciplined acquisitions.
Animal Care Growth And Portfolio ExpansionAnimal Care provides a meaningful growth engine beyond core pharmaceutical distribution. Strong revenue and EBITDA growth, together with broader premium and fresh/chilled offerings, can deepen customer relationships and diversify the group’s earnings mix over the next several quarters.
Cash Generation And Financial FlexibilityPositive free cash flow and leverage within management’s target range give EBOS resilience while funding investment and shareholder distributions. Substantial undrawn facilities and debt maturity beyond three years also provide flexibility to manage operating needs or pursue bolt-on growth.
Bears Say
Revenue And Margin VolatilityThe sharp FY2026 revenue contraction and material gross-margin compression reduce confidence in the stability of EBOS’s reported earnings profile. Even with broadly flat net income, this volatility makes future profitability more dependent on mix, contract timing, and effective cost control.
Community Pharmacy Margin PressurePersistent competition and pharmacy margin pressure can constrain earnings conversion even when prescription and network sales grow. The low group EBITDA margin leaves limited room for adverse mix or reimbursement changes, making sustained productivity and disciplined pricing important to protecting profitability.
New Zealand Contract Roll-offThe known New Zealand contract expiry creates a visible source of earnings pressure within the next several months. Although management estimates the impact at about 1% of group EBITDA, redeployment or restructuring will be needed to replace the volume and preserve network economics.
EBOS Group Limited News
EBO FAQ
What was EBOS Group Limited’s price range in the past 12 months?
EBOS Group Limited lowest share price was AU$14.87 and its highest was AU$26.00 in the past 12 months.
What is EBOS Group Limited’s market cap?
EBOS Group Limited’s market cap is AU$3.50B.
When is EBOS Group Limited’s upcoming earnings report date?
EBOS Group Limited’s upcoming earnings report date is Feb 23, 2027 which is in 119 days.
How were EBOS Group Limited’s earnings last quarter?
EBOS Group Limited released its earnings results on Aug 18, 2026. The company reported AU$0.603 earnings per share for the quarter, beating the consensus estimate of AU$0.595 by AU$0.008.
Is EBOS Group Limited overvalued?
According to Wall Street analysts EBOS Group Limited’s price is currently Undervalued.
Does EBOS Group Limited pay dividends?
EBOS Group Limited pays a Notavailable dividend of AU$0.526 which represents an annual dividend yield of 6.34%. See more information on EBOS Group Limited dividends here
What is EBOS Group Limited’s EPS estimate?
EBOS Group Limited’s EPS estimate is 0.54.
How many shares outstanding does EBOS Group Limited have?
EBOS Group Limited has 209,062,880 shares outstanding.
What happened to EBOS Group Limited’s price movement after its last earnings report?
EBOS Group Limited reported an EPS of AU$0.603 in its last earnings report, beating expectations of AU$0.595. Following the earnings report the stock price went up 8.283%.
Which hedge fund is a major shareholder of EBOS Group Limited?
Currently, no hedge funds are holding shares in AU:EBO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
EBOS Group Limited
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
EBO Stock 12 Month Forecast
Average Price Target
AU$23.31
▲(26.14% Upside)
Technical Analysis
Fisher & Paykel Healthcare Corporation Limited
―
Pacific Edge Limited
―
Ryman Healthcare
―
TruScreen Group Ltd.
―
AFT Pharmaceuticals Ltd.
―








